Skip to content

Impact of Microbial Exposure of the Habitat at the Time of Birth on the Development of Allergic Diseases.

Study of the Impact of Microbial Exposure of the Habitat at the Time of Birth on the Development of Allergic Diseases.

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04189978
Enrollment
320
Registered
2019-12-09
Start date
2019-11-12
Completion date
2022-12-31
Last updated
2022-07-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Allergic Disorder

Brief summary

In 2001-2002, a longitudinal study on the risk of atopic sensitization in children was conducted by the Pneumo-Allergology and Pediatrics departments of the CHU Saint-Pierre Hospital and at the Neonatology Department of the Queen Fabiola Children's University Hospital (HUDERF). The aim of the study was to study bacteria and endotoxins in airborne dust in Brussels homes in order to evaluate their impact on the development of allergic diseases in newborns. Between December 2000 and August 2002, 114 children (67 from HUDERF and 47 from CHU St-Pierre) were included in the study. These were eutrophic children without acquired pathology or known genetics. Simultaneously a microbial habitat assessment was performed based on a detailed description and on endotoxin assays in the airborne and deposited dust (mainly mattress).These data can be used to define habitats with high or low contamination.Samples for microbial analyzes (Gram positive and negative and mold) were also carried out. Preliminary results suggested: 1. A protective effect of airborne dust endotoxins on the risk of developing atopic dermatitis in children at 6 and 12 months of life, 2. An effect of endotoxins promoting the occurrence of wheezing in children after 6 months. In this current, new study, the investigators will recontact the children who were included in the 2003 study. The goal is to evaluate them clinically and allergically and associate the risk of sensitization / allergic diseases with the microbial exposure of the habitat, measured during the neonatal period. Siblings and parents who were exposed during the same period will also be evaluated.

Interventions

DIAGNOSTIC_TESTClinical evaluation

The assessment is based on a comprehensive questionnaire, a simple clinical examination, an spirometry test, allergic skin tests, measurement of the exhaled fraction of NO (FeNO) and blood serum analysis.

Sponsors

Brugmann University Hospital
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
12 Years to No maximum
Healthy volunteers
No

Inclusion criteria

Children who participated in the study conducted in 2001-2002, their parents and the siblings who were exposed to the same environment at this period.

Exclusion criteria

None

Design outcomes

Primary

MeasureTime frameDescription
Prevalence of positivity of allergic skin tests1 yearPrevalence of positivity of allergic skin tests
Prevalence of positivity of ImmunoCAP tests1 yearPrevalence of positivity of ImmunoCAP tests

Secondary

MeasureTime frameDescription
Spirometry results1 yearSpirometry results
Exhaled fraction of NO (FeNO) results1 yearExhaled fraction of NO (FeNO) results
Prevalence of clinical manifestations of allergy1 yearPrevalence of clinical manifestations of allergy (atopic eczema, food allergy, asthma and rhinitis).
Socio-cultural status1 yearSocio-cultural status
Eosinophilia count1 yearEosinophilia count
Prevalence of confirmed asthma1 yearPrevalence of confirmed asthma (clinical manifestations, spirometry and FeNO)

Countries

Belgium

Contacts

Primary ContactOlivier Michel, MD
Olivier.MICHEL@chu-brugmann.be3224773664

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026